

(<http://aphanet.org>)

[Home](#) > Approved for use in younger patients

Generic Name:

Varicella zoster vaccine, live, attenuated

Trade Name:

Zostavax

Company:

Merck

Notes:

[Zostavax](#) was originally approved for patients 60 years and older. Data from a placebo-controlled, double-blind study involving 22,439 patients who were 50 to 59 years of age showed that administration of the vaccine reduced the risk of developing zoster by 69.8% over a median monitoring period of 1.3 years. Injection-site reactions were the most commonly observed adverse events in this patient population.

Medication Monitor Categories:

[Supplemental Approvals](#)

Use:

Prevention of herpes zoster (shingles) in patients 50 to 59 years of age

Source URL: <http://aphanet.org/supplemental-approvals/approved-use-younger-patients>